20-F/A: Bionomics Limited Files Amendment to 20-F Annual Report Regarding Internal Controls

Bionomics Limited has filed an amendment to its annual report on Form 20-F to include management's assessment of internal controls over financial reporting and certifications from the CEO and CFO.

Summary

• Bionomics Limited filed an amendment (Form 20-F/A) to its annual report for the fiscal year ended June 30, 2023.
• The amendment includes management's assessment of the company's internal controls over financial reporting.
• The filing also includes revised certifications from the CEO and CFO regarding the company's internal controls.
• Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2023.
• Management also concluded that the company's internal control over financial reporting was effective as of June 30, 2023, based on criteria set forth in Internal Control Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO 2013).
• There were no changes in internal controls over financial reporting that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting during the period covered by the report.
• The company had 1,486,735,424 ordinary shares outstanding as of the close of business covered by the annual report.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as the company is demonstrating compliance with regulatory requirements and reporting effective internal controls.

Positives

• Management has assessed and concluded that the company's disclosure controls and procedures are effective.
• Management has assessed and concluded that the company's internal control over financial reporting is effective.
• The CEO and CFO have certified the accuracy and reliability of the financial reporting.
• There were no material changes in internal controls over financial reporting during the reporting period.

Risks

• Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Future Outlook

The filing does not reflect events occurring after the filing of the Annual Report and does not modify or update the disclosure therein in any way except as described in the amendment.

Management Comments

• Based upon that evaluation, our Chief Executive Officer, Non-Executive Chairman and Chief Financial Officer concluded that, as of June 30, 2023, our disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level.
• Based on our evaluation under the criteria set forth in Internal Control Integrated Framework, our management concluded that our internal control over financial reporting was effective as of June 30, 2023.

Industry Context

This type of filing is standard for companies listed on U.S. exchanges and reflects compliance with Sarbanes-Oxley Act requirements regarding internal controls over financial reporting.

Comparison to Industry Standards

• The company's assessment of internal controls aligns with the requirements of the Sarbanes-Oxley Act, similar to other publicly listed companies.
• The use of the COSO 2013 framework is a common practice for evaluating internal control effectiveness, consistent with industry standards.
• Many companies in the pharmaceutical and biotechnology sectors, such as Amgen, Gilead Sciences, and Biogen, also conduct similar assessments and certifications of their internal controls.

Stakeholder Impact

• The filing provides assurance to shareholders and other stakeholders regarding the reliability of the company's financial reporting.
• Effective internal controls can help protect the company's assets and prevent fraud, benefiting all stakeholders.

Key Dates

Keywords

internal controls, financial reporting, disclosure controls, Bionomics, 20-F/A, amendment, certification